1231749-99-7

Basic information

• Product Name: 4-chloro-6-(3-methyl-4-nitrophenoxy)pyrimidine
• Synonyms: 4-chloro-6-(3-methyl-4-nitrophenoxy)pyrimidine
• CAS NO: 1231749-99-7
• Molecular Weight: 265.656
• Mol File: 1231749-99-7.mol

Chemical Properties

• CAS DataBase Reference: 4-chloro-6-(3-methyl-4-nitrophenoxy)pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-6-(3-methyl-4-nitrophenoxy)pyrimidine(1231749-99-7)
• EPA Substance Registry System: 4-chloro-6-(3-methyl-4-nitrophenoxy)pyrimidine(1231749-99-7)

Safety Data

• Hazardous Substances Data: 1231749-99-7(Hazardous Substances Data)

Upstream product

• 1193-21-1 4,6-dichloropyrimidine 
• 2581-34-2 3-methyl-4-nitrophenol 

Downstream Products

• 1231750-00-7 7-methoxy-3-(1-(6-(3-methyl-4-nitrophenoxy)pyrimidin-4-yl)piperidin-4-yl)-4,5-dihydro-1H-benzo[d][1,3]diazepine-2(3H)-one 
• 1231748-94-9 N-(4-(6-(4-(7-methoxy-2-oxo-4,5-dihydro-1H-benzo[d][1,3]diazepin-3(2H)-yl)piperidin-1-yl)pyrimidin-4-yloxy)-2-methylphenyl)acetamide 
• 1231748-96-1 3-(1-(6-(4-amino-3-methylphenoxy)pyrimidin-4-yl)piperidin-4-yl)-7-methoxy-4,5-dihydro-1H-benzo[d][1,3]diazepin-2(3H)-one 

Relevant articles and documents

Integrated bioinformatics, computational and experimental methods to discover novel Raf/extracellular-signal regulated kinase (ERK) dual inhibitors against breast cancer cells

Beginning with our previously reported ERK inhibitor BL-EI001, we found Raf1 to be an important regulator in the ERK interactive network, and then we designed and synthesized a novel series of Raf1/ERK dual inhibitors against human breast cancers through integrative computational, synthetic and biological screening methods. Moreover, we found that compound 9d suppressed the proliferation of breast cancer cell lines and induced cellular apoptosis via a mitochondrial pathway with only partial dependence on Raf1 and ERK. Our results suggest that an integrative method including in silico design, chemical synthesis, biological screening and bioinformatics analysis could be an attractive strategy for the discovery of multi-target inhibitors against breast cancer.

Novel Compounds

The present invention relates to the new compounds of general formula I wherein A, U, V, X, Y, R1, R2 and R3 are defined as stated hereinafter, the tautomers, the isomers thereof, the diastereomers, the enantiomers, the hydrates, the mixtures and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, their use and processes for preparing them.